93 related articles for article (PubMed ID: 24872435)
1. Evaluation of antibody-chemokine fusion proteins for tumor-targeting applications.
Hess C; Neri D
Exp Biol Med (Maywood); 2014 Jul; 239(7):842-852. PubMed ID: 24872435
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
3. The dose-dependent tumor targeting of antibody-IFNγ fusion proteins reveals an unexpected receptor-trapping mechanism in vivo.
Hemmerle T; Neri D
Cancer Immunol Res; 2014 Jun; 2(6):559-67. PubMed ID: 24795141
[TBL] [Abstract][Full Text] [Related]
4. Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily.
Hemmerle T; Hess C; Venetz D; Neri D
J Biotechnol; 2014 Feb; 172():73-6. PubMed ID: 24384233
[TBL] [Abstract][Full Text] [Related]
5. A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo.
Villa A; Trachsel E; Kaspar M; Schliemann C; Sommavilla R; Rybak JN; Rösli C; Borsi L; Neri D
Int J Cancer; 2008 Jun; 122(11):2405-13. PubMed ID: 18271006
[TBL] [Abstract][Full Text] [Related]
6. The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel.
Pasche N; Wulhfard S; Pretto F; Carugati E; Neri D
Clin Cancer Res; 2012 Aug; 18(15):4092-103. PubMed ID: 22693354
[TBL] [Abstract][Full Text] [Related]
7. Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads.
Schmid AS; Tintor D; Neri D
J Biotechnol; 2018 Apr; 271():29-36. PubMed ID: 29438784
[TBL] [Abstract][Full Text] [Related]
8. Alternatively Spliced EDA Domain of Fibronectin Is a Target for Pharmacodelivery Applications in Inflammatory Bowel Disease.
Bootz F; Schmid AS; Neri D
Inflamm Bowel Dis; 2015 Aug; 21(8):1908-17. PubMed ID: 25993691
[TBL] [Abstract][Full Text] [Related]
9. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation.
Frey K; Zivanovic A; Schwager K; Neri D
Integr Biol (Camb); 2011 Apr; 3(4):468-78. PubMed ID: 21225052
[TBL] [Abstract][Full Text] [Related]
10. Targeted delivery of calreticulin to ED-A fibronectin leads to tumor-growth retardation.
Ziffels B; Grötsch A; Al-Bayati L; Neri D
J Biotechnol; 2019 Jan; 290():53-58. PubMed ID: 30579890
[TBL] [Abstract][Full Text] [Related]
11. Antibody-mediated delivery of interleukin 4 to the neo-vasculature reduces chronic skin inflammation.
Hemmerle T; Zgraggen S; Matasci M; Halin C; Detmar M; Neri D
J Dermatol Sci; 2014 Nov; 76(2):96-103. PubMed ID: 25190364
[TBL] [Abstract][Full Text] [Related]
12. The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model.
Schwager K; Bootz F; Imesch P; Kaspar M; Trachsel E; Neri D
Hum Reprod; 2011 Sep; 26(9):2344-52. PubMed ID: 21705369
[TBL] [Abstract][Full Text] [Related]
13. Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7.
Pasche N; Woytschak J; Wulhfard S; Villa A; Frey K; Neri D
J Biotechnol; 2011 Jun; 154(1):84-92. PubMed ID: 21527292
[TBL] [Abstract][Full Text] [Related]
14. Antibody-Based Targeted Delivery of Interleukin-22 Promotes Rapid Clinical Recovery in Mice With DSS-Induced Colitis.
Bootz F; Ziffels B; Neri D
Inflamm Bowel Dis; 2016 Sep; 22(9):2098-105. PubMed ID: 27482975
[TBL] [Abstract][Full Text] [Related]
15. Antibody-based delivery of interleukin-9 to neovascular structures: Therapeutic evaluation in cancer and arthritis.
Gouyou B; Ongaro T; Cazzamalli S; De Luca R; Kerschenmeyer A; Valet P; Villa A; Neri D; Matasci M
Exp Biol Med (Maywood); 2021 Apr; 246(8):940-951. PubMed ID: 33475433
[TBL] [Abstract][Full Text] [Related]
16. Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications.
Steiner M; Gutbrodt K; Krall N; Neri D
Bioconjug Chem; 2013 Feb; 24(2):234-41. PubMed ID: 23350721
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma.
Wieckowski S; Hemmerle T; Prince SS; Schlienger BD; Hillinger S; Neri D; Zippelius A
Lung Cancer; 2015 Apr; 88(1):9-15. PubMed ID: 25682318
[TBL] [Abstract][Full Text] [Related]
18. The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer.
Hemmerle T; Neri D
Int J Cancer; 2014 Jan; 134(2):467-77. PubMed ID: 23818211
[TBL] [Abstract][Full Text] [Related]
19. The antibody-mediated targeted delivery of interleukin-13 to syngeneic murine tumors mediates a potent anticancer activity.
Hess C; Neri D
Cancer Immunol Immunother; 2015 May; 64(5):635-44. PubMed ID: 25722088
[TBL] [Abstract][Full Text] [Related]
20. A Novel Antibody-IL15 Fusion Protein Selectively Localizes to Tumors, Synergizes with TNF-based Immunocytokine, and Inhibits Metastasis.
Corbellari R; Stringhini M; Mock J; Ongaro T; Villa A; Neri D; De Luca R
Mol Cancer Ther; 2021 May; 20(5):859-871. PubMed ID: 33632875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
